Jason Zemansky
BofA Securities, Research Division

Welcome to the afternoon session on this, our first day of the Annual Healthcare Conference in Toasty Las Vegas. My name is Jason Zemansky, and one of the mid-cap analysts here at BofA. Very pleased to have join me the team from BridgeBio. I have Thomas Trimarchi, CFO and President; and Chinmay Shukla, Vice President, Strategic Finance. Gentlemen, thank you so much for joining us.

Thomas Trimarchi
CFO & President

Thank you for having us. It's great to be back in sunny Las Vegas here with you.

Jason Zemansky
BofA Securities, Research Division

Excellent. So we'll end with maybe 2 or 3 minutes. So, if you have a question from the audience, we'll pass around a microphone. In the meantime, maybe let's start with a little bit of background for those newer to the story. Can you just give us an overview of BridgeBio and Attruby?

Thomas Trimarchi
CFO & President

Yes, sure. I can start and maybe pass it over to Chinmay to fill in some blanks. So BridgeBio is a biotech company that was founded just over 10 years ago now, and we were created to do 2 things. One was to deliver as many meaningful medicines as we can to patients in the shortest-possible time frame. And two was to really be focused on things like NPV and cost of capital so we could make our business sustainable, so, we could be around for generations and generations to leave a big impact on the world and hopefully deliver a lot of medicines to patients